Market Overview

Therachon Raises $60 Million Mezzanine Financing to Advance Lead Program in Achondroplasia and to Expand Rare Disease Pipeline

Share:

- Jørgen Søberg Petersen, M.D., Ph.D., DMSc, MBA and Timothy
Anderson to Join Board of Directors -

Therachon AG, a clinical-stage biotechnology company focused on rare
diseases, today announced it has completed a $60 million mezzanine
financing led by Novo Holdings and joined by new investors Cowen
Healthcare Investments, Pfizer Ventures and funds managed by Tekla
Capital Management LLC. Existing investors Versant Ventures, OrbiMed,
Bpifrance and Inserm Transfert Initiative also participated.

Therachon plans to use the proceeds to advance the company's lead
pipeline candidate TA-46, a novel protein therapeutic for
achondroplasia, the most common form of disproportionate short stature
in humans, as well as to support the expansion of its rare disease
pipeline. TA-46 is being developed as a weekly subcutaneous therapy for
children and adolescents living with achondroplasia.

Therachon is currently conducting a Phase 1 randomized,
placebo-controlled, double-blind trial to evaluate the safety,
tolerability and pharmacokinetics of single and multiple increasing
doses of TA-46 in healthy volunteers. Therachon has also recently
started a natural history study called the ‘Dreambird study,' that will
prospectively assess the burden of complications of achondroplasia in
approximately 200 children across multiple sites in Europe, Canada and
the United States and will enable the start of treatment studies in
children with achondroplasia in 2019.

"We are very pleased to receive strong support from such a distinguished
and international syndicate of investors who are committed to our vision
and support our growth as a clinical-stage company," said Luca
Santarelli, M.D., chief executive officer at Therachon. "With this
financing, we will be able to devote more resources to our lead clinical
program in achondroplasia. Additionally, we look forward to exploring
additional pipeline opportunities in the rare disease space."

New Board Appointments
In conjunction with this financing,
Jørgen Søberg Petersen M.D., Ph.D., DMSc, MBA, venture partner at Novo
Holdings, and Timothy Anderson, director, Cowen Healthcare Investments,
have been appointed members of Therachon's Board of Directors.

"We are delighted to welcome Jørgen and Tim to our team," said Thomas F.
Woiwode, Ph.D., managing director at Versant Ventures and Chairman of
the Board at Therachon. "Their combined experience brings a wide range
of financial and healthcare experience that will be invaluable as
Therachon continues its evolution as a clinical-stage company and moves
into the next stages of growth."

"We are pleased to lead this European investment with a strong syndicate
of US investors who share our perspective on Therachon's potential as a
promising European rare disease company," said Dr. Petersen.

Dr. Petersen has been a venture partner at Novo Holdings since September
2017. After nine years in clinical and academic medicine in Denmark and
the United States, Dr. Petersen spent 18 years in senior research and
development roles in Denmark, Switzerland, the United States, France and
Germany. He co-founded and built the Nasdaq-listed biotech company
Zealand Pharma (ZEAL.CO), established the Immunology franchise at Merck,
and has held leadership roles at Lundbeck and Novo Nordisk. He has
industrial research and development experience across multiple
therapeutic areas, including CNS, cardiovascular disease, diabetes,
oncology and autoimmune disease, and has been involved in a number of
major pharmaceutical licensing deals and alliances. Mr. Petersen
received his M.D., Ph.D. and DMSc from the University of Copenhagen and
an Executive MBA degree from the Technical University of Denmark.

Mr. Anderson is director and co-founder of Cowen Healthcare Investments,
a private investment fund sponsored by an affiliate of Cowen Inc., a
diversified financial services firm. In addition, he also serves on the
board of Compass Therapeutics and the investment committee of Lagunita
Biosciences. Prior to Cowen Healthcare Investments, Mr. Anderson was an
investment banker in Cowen and Company's healthcare investment practice.
He received his Bachelor's degree from Bowdoin College.

About Therachon
Therachon is a clinical-stage global
biotechnology company focused on developing medicines for rare diseases
with significant unmet need. The company's lead pipeline candidate,
TA-46, is a novel protein therapy in development for achondroplasia, the
most common form of disproportionate short stature in humans. Therachon
is committed to translating the promise of its science into new
treatments for patients with high unmet medical needs. For more
information, visit www.therachon.com.

Visit us on Twitter.
Visit us on LinkedIn.

View Comments and Join the Discussion!